NASDAQ: IPSCCentury Therapeutics Inc Stock
$2.19+0.06 (+2.82%)
Updated Apr 6, 2026
IPSC Price
$2.19
Fair Value Price
N/A
Market Cap
$393.59M
52 Week Low
$0.34
52 Week High
$3.04
P/E
-15.64x
P/B
2.48x
P/S
0.79x
PEG
N/A
Dividend Yield
N/A
Revenue
$109.16M
Earnings
-$9.58M
Gross Margin
100%
Operating Margin
-8.84%
Profit Margin
-8.8%
Debt to Equity
0.41
Operating Cash Flow
-$104M
Beta
1.35
Next Earnings
May 20, 2026
Ex-Dividend
N/A
Next Dividend
N/A
IPSC Overview
Century Therapeutics Incorporated is a biotech company developing transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also advancing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma. Century Therapeutics was founded in 2018 and is headquartered in Philadelphia, PA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IPSC's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IPSC
Ranked#182 of 460
Ranked#182 of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $186.85 | A | |
| $23.02 | A | |
| $16.00 | A |
Be the first to know about important IPSC news, forecast changes, insider trades & much more!
IPSC News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IPSC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IPSC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IPSC is good value based on its book value relative to its share price (2.48x), compared to the US Biotechnology industry average (4.75x)
P/B vs Industry Valuation
IPSC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more IPSC due diligence checks available for Premium users.
Valuation
IPSC fair value
Fair Value of IPSC stock based on Discounted Cash Flow (DCF)
Price
$2.19
Fair Value
-$0.25
Undervalued by
982.07%
IPSC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IPSC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-15.64x
Industry
28.11x
Market
30.09x
IPSC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.48x
Industry
4.75x
IPSC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IPSC's financial health
Profit margin
Revenue
$0.0
Net Income
-$19.2M
Profit Margin
0%
IPSC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IPSC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$223.7M
Liabilities
$64.8M
Debt to equity
0.41
IPSC's short-term assets ($120.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IPSC's short-term assets ($120.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IPSC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IPSC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.1M
Investing
$22.4M
Financing
$53.0k
IPSC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IPSC vs Biotech Stocks
Century Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.